Back to today’s briefing

Story perspectives

Revolutionary mRNA Vaccine Shows Promise Against Pancreatic Cancer

4/9/2025

50 10

Summary

Story summary

A groundbreaking personalized mRNA vaccine for pancreatic cancer, developed by researchers at Memorial Sloan Kettering Cancer Center, has demonstrated remarkable immune responses lasting over three years. Known as autogene cevumeran, this innovative treatment generates T cells that endure for decades, drastically lowering recurrence rates. Exciting ongoing studies are set to investigate its potential against other cancers.

1 of 1

Story summary

A groundbreaking personalized mRNA vaccine for pancreatic cancer, developed by researchers at Memorial Sloan Kettering Cancer Center, has demonstrated remarkable immune responses lasting over three years. Known as autogene cevumeran, this innovative treatment generates T cells that endure for decades, drastically lowering recurrence rates. Exciting ongoing studies are set to investigate its potential against other cancers.